Jump to: navigation, search
Clinical data
  • C
Routes of
ATC code
Legal status
Legal status
  • Unlicensed
Pharmacokinetic data
Elimination half-life1.6 - 1.9 hours
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass319.4 g/mol
3D model (JSmol)

WikiDoc Resources for Cilansetron


Most recent articles on Cilansetron

Most cited articles on Cilansetron

Review articles on Cilansetron

Articles on Cilansetron in N Eng J Med, Lancet, BMJ


Powerpoint slides on Cilansetron

Images of Cilansetron

Photos of Cilansetron

Podcasts & MP3s on Cilansetron

Videos on Cilansetron

Evidence Based Medicine

Cochrane Collaboration on Cilansetron

Bandolier on Cilansetron

TRIP on Cilansetron

Clinical Trials

Ongoing Trials on Cilansetron at Clinical

Trial results on Cilansetron

Clinical Trials on Cilansetron at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cilansetron

NICE Guidance on Cilansetron


FDA on Cilansetron

CDC on Cilansetron


Books on Cilansetron


Cilansetron in the news

Be alerted to news on Cilansetron

News trends on Cilansetron


Blogs on Cilansetron


Definitions of Cilansetron

Patient Resources / Community

Patient resources on Cilansetron

Discussion groups on Cilansetron

Patient Handouts on Cilansetron

Directions to Hospitals Treating Cilansetron

Risk calculators and risk factors for Cilansetron

Healthcare Provider Resources

Symptoms of Cilansetron

Causes & Risk Factors for Cilansetron

Diagnostic studies for Cilansetron

Treatment of Cilansetron

Continuing Medical Education (CME)

CME Programs on Cilansetron


Cilansetron en Espanol

Cilansetron en Francais


Cilansetron in the Marketplace

Patents on Cilansetron

Experimental / Informatics

List of terms related to Cilansetron

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Cilansetron is a drug that is a 5HT-3 antagonist currently under trial phase in the EU and US it is manufactured by Solvay Pharmaceuticals INC.

5HT-3 receptors are responsible for causing many things from nausea to excess bowel movements. It is thought in conditions like irritable bowel syndrome (IBS) the receptors have become faulty or oversensitive. 5HT-3 antagonists work by blocking the nervous and chemical signals from reaching these receptors.

Studies have shown that the drug can greatly improve quality of life in men and women with diahorrea predominant IBS (1) Cilansetron is the first 5HT antagonist specifically designed for IBS that is effective in men as well as women.(1)

Solvay has had considerable difficulty with the medicines regulators in the UK, EU and USA with regards to licensing the drug. This could possibly be due to the problems discovered after licensing with the drug Lotronex. At time of writing; Solvay had recently withdrawn its application to the U.S. Food and Drug Administration (FDA) but was continuing its talks with the MHRA in the UK and EU regulators. (2)

It is not currently known what sort of timeframe the public are looking at to be able to obtain the drug. This matter is not helped by the lack of information about cilansetron and its trials in the public domain. The regulators have also stated this in their responses.[citation needed]

There is no information about future trials currently available.

Some people have tried the Anti-emetic ondansetron HCl (Zofran) as a substitute for the time being, results are mixed but noted effect has been shown in some males and females (3) However; due to its license in the UK it is usually only prescribable at consultant level. Since the licensing of a generic version it is more likely an NHS prescription will be accepted as the branded version is very expensive (Official NHS pricing.) In the USA and Canada: availability often depends on insurance and the doctors personal opinion on off-label prescribing.


  1. (General info on Cilansetron.)
  2.,,36423-2-0,00.htm#contact (Sovay press relaase 19 November 2005.)
  3. (Clinical trial for 5-HT3 antagonists use in Diarrhoea-predominant IBS)